EcoDrugPlus

Chemokine (C-X-C Motif) Receptor 4a

Ensembl ID : ENSNBRG00000020093
Gene Symbol: CXCR4A
2 Cross references
201 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSNBRG00000000971
Gene Symbol: CCKAR
4 Cross references
200 Possible Orthologues:

Cholecystokinin B Receptor

Ensembl ID : ENSNBRG00000006931
Gene Symbol: CCKBR
4 Cross references
191 Possible Orthologues:

Cholecystokinin Receptor-Like

Ensembl ID : ENSNBRG00000021142
Gene Symbol: LOC102798776
3 Cross references
193 Possible Orthologues:

Cholesteryl Ester Transfer Protein-Like

Ensembl ID : ENSNBRG00000017643
Gene Symbol: LOC102780829
3 Cross references
137 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSNBRG00000023688
Gene Symbol: CHRM3
3 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSNBRG00000015225
Gene Symbol: CHRM3
3 Cross references
187 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSNBRG00000010964
Gene Symbol: CHRNA3
3 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSNBRG00000005296
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSNBRG00000011015
Gene Symbol: CHRNB4
3 Cross references
193 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5a

Ensembl ID : ENSNBRG00000002467
Gene Symbol: CHRM5A
1 Cross references
195 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSNBRG00000020074
Gene Symbol: F2R
1 Cross references
248 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).